Evidence map›Paper›PMID 27619636›Full record

ArticlePharmacology, biochemistry, and behavior

Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery.

Nia M Harris, Rodney Ritzel, Nickolas S Mancini, Yuhang Jiang, Xiang Yi, Devika S Manickam, William A Banks, Alexander V Kabanov, Louise D McCullough, Rajkumar Verma

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology, biochemistry, and behavior. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nia M HarrisDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT 06032, USA.
Rodney RitzelDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT 06032, USA.
Nickolas S ManciniDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT 06032, USA.
Yuhang JiangCenter for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, NC 27599-7362, USA.
Xiang YiCenter for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, NC 27599-7362, USA.
Devika S ManickamCenter for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, NC 27599-7362, USA.
William A BanksGeriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA; Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98108, USA.
Alexander V KabanovCenter for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,, Chapel Hill, NC 27599-7362, USA.
Louise D McCulloughDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT 06032, USA; Department of Neurology, University of Texas Health Science Center, Houston, TX 77030, USA.
Rajkumar VermaDepartment of Neuroscience, University of Connecticut Health Center, Farmington, CT 06032, USA. Electronic address: raverma@uchc.edu.
UConn Health · USUniversity of North Carolina at Chapel Hill · USUniversity of Puget Sound · US

Funding

Psychosocial Stress and Behavioral Response to StrokeR01NS077769 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MCCULLOUGH, LOUISE D. · 2011 to 2014
$2.3M
Nanoformulation of the BDNF for treatment of strokeR21NS088152 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KABANOV, ALEXANDER V · 2015 to 2016
$783k
NINDS NIH HHS R01 NS077769NINDS NIH HHS R21 NS088152
6 · The paper itself

Abstract

backgroundLow levels of brain-derived neurotrophic factor (BDNF) are linked to delayed neurological recovery, depression, and cognitive impairment following stroke. Supplementation with BDNF reverses these effects. Unfortunately, systemically administered BDNF in its native form has minimal therapeutic value due to its poor blood brain barrier permeability and short serum half-life. In this study, a novel nano-particle polyion complex formulation of BDNF (nano-BDNF) was administered to mice after experimental ischemic stroke.

methodsMale C57BL/6J (8-10weeks) mice were randomly assigned to receive nano-BDNF, native-BDNF, or saline treatment after being subjected to 60min of reversible middle cerebral artery occlusion (MCAo). Mice received the first dose at 3 (early treatment), 6 (intermediate treatment), or 12h (delayed treatment) following stroke onset; a second dose was given in all cohorts at 24h after stroke onset. Post-stroke outcome was evaluated by behavioral, histological, and molecular analysis for 15days after stroke.

resultsEarly and intermediate nano-BDNF treatment led to a significant reduction in cerebral tissue loss. Delayed treatment led to improved memory/cognition, reduced post-stroke depressive phenotypes, and maintained myelin basic protein and brain BDNF levels, but had no effect on tissue atrophy.

conclusionsThe results indicate that administration of a novel nano-particle formulation of BDNF leads to both neuroprotective and neuro-restorative effects after stroke.

Indexed as

AnimalsBehavior, AnimalBrain-Derived Neurotrophic FactorBrain IschemiaCyclic AMP Response Element-Binding ProteinDepressionDrug CompoundingDrug Delivery SystemsMaleMemoryMiceMice, Inbred C57BLNanoparticlesBrain-Derived Neurotrophic FactorCreb1 protein, mouseCyclic AMP Response Element-Binding ProteinBDNFDepressive behaviorNeuroprotectionNeuro-restorativeStroke

Identifiers

PMID27619636
PMCPMC5145740
OpenAlexW2519992565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.